Durability Still In Question For Acadia's Nuplazid In Alzheimer’s Psychosis

Full Phase II data studying Acadia's Nuplazid (pimavanserin) in patients with Alzheimer’s disease psychosis confirmed the exploratory drug met its primary endpoint, but worries remain over the drug's durability – and hence its commercial promise in dementia-related psychosis.

Elderly man
Acadia's Nuplazid Data In Alzheimer’s Disease Psychosis Is Mixed • Source: Shutterstock

More from Clinical Trials

More from R&D